For the month of December, CEO Julie Kampf of JBK Associates International kicked off a month-long series with CBS-12 News.
JUPITER, Fla., Feb. 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors.